Imunovir 500mg Tablets *

  • Company:

    Kora Healthcare
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 26 June 2017

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - how to report a side effect

Updated on 26 June 2017

File name

PIL_15458_441.pdf

Reasons for updating

  • New PIL for new product

Updated on 14 August 2015

Reasons for updating

  • Change to drug interactions
  • Addition of information on reporting a side effect.

Updated on 11 March 2015

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In Section 4.4 the following text has been added:

In some people acute hypersensitivity reactions (urticarial, angioedema, anaphylaxis) may occur. Treatment with Imunovir should be withdrawn in these cases.

Imunovir contains wheat starch. Suitable for people with coeliac disease. Patients with wheat allergy (different from coeliac disease) should not take this medicine.

In Section 4.5 the following text has been added:

Isoprinosine may be administered after but not concomitantly with immunosuppressive agents, as there may be a pharmacokinetic influence on the desired therapeutic effects.

Concomitant use with AZT increases AZT nucleotide formation through multiple mechanisms involving increased plasma AZT bioavailability and increased intracellular phosphorylation in human blood monocytes.
As a result Imunovir increases the effect of AZT.

Section 4.8 has been reformatted and includes the details for reporting of suspected adverse reactions.

Updated on 11 March 2015

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 24 August 2012

Reasons for updating

  • New PIL for medicines.ie

Updated on 03 April 2012

Reasons for updating

  • New SPC for medicines.ie

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided